-
Tytuł:
-
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
-
Autorzy:
-
Huang YH; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
Hsu KH; Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Chin CS; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Tseng JS; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Yang TY; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Chen KC; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Su KY; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yu SL; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Center of Genomic and Precision Medicine, National Taiwan University, Taipei,Taiwan.; Institute of Medical Device and Imaging, College of Medicine, National Taiwan University, Taipei, Taiwan.; Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen JJW; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.
Chang GC; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
-
Źródło:
-
Cancer research and treatment [Cancer Res Treat] 2022 Apr; Vol. 54 (2), pp. 434-444. Date of Electronic Publication: 2021 Aug 02.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Seoul, Korea : The Association,
-
MeSH Terms:
-
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Afatinib/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; ErbB Receptors/genetics ; Erlotinib Hydrochloride/adverse effects ; Gefitinib/therapeutic use ; Humans ; Mutation ; Protein Kinase Inhibitors/adverse effects
-
References:
-
Pharmaceuticals (Basel). 2020 Oct 23;13(11):. (PMID: 33113888)
Cancer Res Treat. 2018 Oct;50(4):1294-1303. (PMID: 29334606)
Lancet Oncol. 2016 May;17(5):577-89. (PMID: 27083334)
J Thorac Oncol. 2014 Feb;9(2):154-62. (PMID: 24419411)
Clin Cancer Res. 2013 Apr 15;19(8):2240-7. (PMID: 23470965)
N Engl J Med. 2018 Jan 11;378(2):113-125. (PMID: 29151359)
Br J Cancer. 2015 Nov 17;113(10):1519-28. (PMID: 26461059)
N Engl J Med. 2020 Jan 2;382(1):41-50. (PMID: 31751012)
JAMA Oncol. 2021 Mar 01;7(3):386-394. (PMID: 33410885)
Lancet Oncol. 2019 May;20(5):625-635. (PMID: 30975627)
J Clin Oncol. 2012 Feb 1;30(4):433-40. (PMID: 22215752)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
Clin Cancer Res. 2021 Feb 15;27(4):992-1002. (PMID: 33046516)
J Formos Med Assoc. 2021 Sep;120(9):1729-1739. (PMID: 33865672)
Semin Cancer Biol. 2020 Apr;61:167-179. (PMID: 31562956)
Eur Respir J. 2012 Mar;39(3):677-84. (PMID: 21719485)
Future Oncol. 2020 Dec;16(34):2799-2808. (PMID: 32854536)
Lancet Oncol. 2017 Nov;18(11):1454-1466. (PMID: 28958502)
Clin Lung Cancer. 2019 Mar;20(2):134-138. (PMID: 30514667)
JAMA Oncol. 2018 May 1;4(5):739-742. (PMID: 29596544)
Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:4-12. (PMID: 21585703)
Transl Lung Cancer Res. 2021 Jan;10(1):183-192. (PMID: 33569303)
Lancet Oncol. 2019 Dec;20(12):1655-1669. (PMID: 31591063)
J Thorac Dis. 2019 Nov;11(11):4507-4515. (PMID: 31903239)
JAMA Oncol. 2019 Oct 01;5(10):1448-1455. (PMID: 31393548)
J Clin Oncol. 2009 Mar 10;27(8):1227-34. (PMID: 19188680)
Lung Cancer. 2018 Jan;115:103-108. (PMID: 29290249)
Oncol Ther. 2021 Dec;9(2):489-503. (PMID: 33990928)
JAMA Oncol. 2020 Jul 1;6(7):1048-1054. (PMID: 32463456)
JAMA. 2014 May 21;311(19):1998-2006. (PMID: 24846037)
Lancet Oncol. 2014 Oct;15(11):1236-44. (PMID: 25175099)
Cancer Res Treat. 2019 Apr;51(2):502-509. (PMID: 29898592)
ESMO Open. 2021 Jun;6(3):100115. (PMID: 33984681)
J Natl Cancer Inst. 2017 Jun 1;109(6):. (PMID: 28376144)
PLoS One. 2015 Mar 19;10(3):e0120852. (PMID: 25789627)
-
Contributed Indexing:
-
Keywords: Adenocarcinoma; Bevacizumab; ErbB receptors; Lung neoplasms; Tyrosine kinase inhibitor
-
Substance Nomenclature:
-
0 (Protein Kinase Inhibitors)
2S9ZZM9Q9V (Bevacizumab)
41UD74L59M (Afatinib)
DA87705X9K (Erlotinib Hydrochloride)
EC 2.7.10.1 (EGFR protein, human)
EC 2.7.10.1 (ErbB Receptors)
S65743JHBS (Gefitinib)
-
Entry Date(s):
-
Date Created: 20210806 Date Completed: 20220419 Latest Revision: 20220716
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9016311
-
DOI:
-
10.4143/crt.2021.671
-
PMID:
-
34352999
-
Purpose: The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients.
Materials and Methods: From August 2016 to October 2020, we enrolled advanced lung adenocarcinoma patients harboring exon 19 deletion or L858R receiving gefitinib, erlotinib and afatinib plus bevacizumab as the first-line treatment for the purposes of analysis.
Results: A total of 36 patients were included in the final analysis. Three patients received gefitinib, 17 received erlotinib, and 16 received afatinib combined with bevacizumab as the first-line treatment. The objective response rate was 77.8%, and disease control rate was 94.4%. The overall median progression-free survival (PFS) was 16.4 months, while the median PFS was 17.1 months in patients with exon 19 deletion, and 16.2 months in patients with L858R mutation (p=0.311). Regarding the use of different EGFR-TKIs, the median PFS was 17.1 months in the erlotinib group and 21.6 months in the afatinib group (p=0.617). In patients with brain metastasis at baseline, the median PFS was 18.9 months in the erlotinib group and 16.4 months in the afatinib group (p=0.747). Amongst patients harboring exon 19 deletion, the median PFS was 16.2 months in the erlotinib group and not-reached in the afatinib group (p=0.141). In patients with L858R mutation, the median PFS was 18.9 months in the erlotinib group and 16.2 months in the afatinib group (p=0.481).
Conclusion: Our research demonstrates that not only erlotinib combined with bevacizumab, but also afatinib plus bevacizumab as first-line treatment, provides solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients.
